E
AGIO icon

Ergoteles’s Agios Pharmaceuticals AGIO Stock Holding History

Ergoteles’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-53,129
Closed -$1.5M – 49
2023
Q2 		$1.5M Buy
53,129
+27,644
+108% +$688K 0.07% 346
2023
Q1 		$585K Buy
+25,485
New +$677K 0.02% 681
2022
Q3 		– Sell
-17,533
Closed -$389K – 1506
2022
Q2 		$389K Buy
17,533
+5,441
+45% +$123K 0.01% 971
2022
Q1 		$352K Sell
12,092
-53,732
-82% -$1.64M 0.01% 792
2021
Q4 		$2.16M Buy
+65,824
New +$2.65M 0.08% 245
2021
Q2 		– Sell
-76,419
Closed -$3.95M – 1463
2021
Q1 		$3.95M Buy
76,419
+34,907
+84% +$1.73M 0.12% 194
2020
Q4 		$1.8M Buy
41,512
+8,545
+26% +$338K 0.06% 262
2020
Q3 		$1.15M Buy
+32,967
New +$1.44M 0.15% 129

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles's AGIO Position: Q3 2023 in Review

Ergoteles sold out of Agios Pharmaceuticals (AGIO) in Q3 2023, closing a stake of 53,129 shares — an estimated $1.5M sold.

Ergoteles first reported a position in AGIO in Q3 2020 and held it in 8 quarters. The position peaked at $3.95M in Q1 2021. 145 funds tracked by Wall St. Rank hold AGIO as of Q3 2023.

  • Ergoteles reported no remaining Agios Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 53,129 Agios Pharmaceuticals shares in Q3 2023, an estimated $1.5M.
  • Ergoteles first reported a position in Agios Pharmaceuticals in Q3 2020 and held it in 8 quarters.
  • Ergoteles's Agios Pharmaceuticals position peaked at $3.95M in Q1 2021.
  • 145 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.